A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study of the Efficacy and Safety of ALV003 Treatment in Symptomatic Celiac Disease Patients Maintained on a Gluten-Free Diet

Location:

Rochester, Minn., Jacksonville, Fla., Phoenix/Scottsdale, Ariz.

Trial status:

Open for Enrollment

Why is this study being done?

To determine the effects of 12 weeks administration of different dose levels of ALV003 on the mucosal lining of the small intestine and symptoms in celiac disease patients.

Who is eligible to participate?

Inclusion Criteria: - Ages 18 to 80 years - Physician diagnosed celiac disease - Adherence to a gluten-free diet - Experiencing symptoms of celiac disease over a 1-month period - Willing to take study medication for 12 weeks - Willing to comply with all study procedures - Sign informed consent Exclusion Criteria: - Active inflammatory bowel disease - Active dermatitis herpetiformis - Use of certain specific medications prior to entry - History of alcohol or illicit drug abuse in previous 6 months - Pregnant or lactating - Received any experimental drug within 30 days of enrollment - Uncontrolled chronic disease or condition

Last updated:

8/20/2014

NCT ID:

NCT01917630

IRB Number:

12-009541